Clinical Trials Browser

Phase 1/2 × Recurrence × Ramucirumab × Clear all

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence